FTC Suing AbbVie, Teva Over Generic AndroGel Pay-for-Delay

Drug Industry Daily
A A
The Federal Trade Commission is suing AbbVie and its partner Besins Healthcare, along with generic firm Teva, over an alleged pay-for-delay deal that put off generic entry of AbbVie and Besins’s blockbuster testosterone gel AndroGel 1%.

To View This Article:

Login

Subscribe To Drug Industry Daily